Clinical Evidence for GLP-1 Receptor Agonists in Alzheimer's Disease: A Systematic Review.

ABSTRACT:

Background

Alzheimer's disease (AD) is the most common cause of dementia. While preclinical studies have shown benefits of glucagon-like peptide 1 receptor agonists (GLP-1 RA) in targeting core AD pathology, clinical studies are limited.

Objective

A systematic review was performed to evaluate GLP-1 RAs in AD for their potential to target core AD pathology and improve cognition.

Methods

Searches were conducted via three different databases (PubMed, Embase, and Cochrane Library). Search terms included Medical Subject Headings (MeSH) terms: 'glucagon-like peptide 1 receptor agonist' and 'Alzheimer's disease', as well as entry terms 'GLP-1 RA', 'AD', and three types of GLP-1 RA: 'liraglutide', 'exenatide', and 'lixisenatide'.

Results

A total of 1,444 studies were s

SUBMITTER: Liang Y 

PROVIDER: S-EPMC11091751 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature